Abstract:Key PointsScientific advancement in neuroscience has not been effectively translated into therapies for neurological diseases. In general, 'toxin reducing' approaches (for example, lowering amyloid-β (Aβ)) thus far have not resulted in halting or delaying disease progression. A paradigm shift in the discovery of disease-modifying therapies for neurological diseases is urgently needed.For neurodegenerative diseases, targeting the pathophysiology rather than the pathogenesis may be more effective to achieve therapeutic intervention. The toxin reducing approach may work if treatment starts very early on in the disease process.Synapse degeneration is a major pathophysiological feature that correlates with disease progression in multiple neurodegenerative diseases. Neuronal loss is irreversible, whereas synapses can be repaired and regenerated.Three aspects of synaptic physiology can be targeted: synaptic transmission, synaptic plasticity and synaptic growth. For disease-modifying therapy, synaptic plasticity and, more importantly, synaptic growth should be targeted.Brain-derived neurotrophic factor (BDNF) is an exemplar of synaptic repair therapy, as it regulates all three aspects of synaptic physiology. It protects and repairs existing synapses and stimulates new synapse formation, even in the presence of various toxins.In humans, the BDNF Val66Met polymorphism in conjunction with high Aβ deposits confers faster decline in Alzheimer's disease endophenotypes such as episodic memory and hippocampal volume, and therefore could be considered as a patient stratification strategy for clinical trials with enhanced sensitivity and robustness.Success of a 'synaptic repair' therapy depends on whether synaptic dysfunction and synaptic repair and/or regeneration can be measured in the clinic. Efforts should be made to develop sensitive and reliable methodologies to measure synaptic function in humans in vivo.Opportunities and challenges in developing BDNF–TRKB pathway-based therapies, including delivery, are discussed.A combination of synaptic therapy and a more reliable and sensitive method (or methods) to measure synaptic changes may pave the way for developing disease-modifying medicines for debilitating neurological diseases. This Review highlights recent discoveries, discusses emerging concepts and proposes synapse-based therapies for treating neurodegenerative diseases.

Development of neurotrophic molecules for treatment of neurodegeneration

Stem Cells for the Treatment of Neurodegenerative Diseases

The Therapeutic Potentials of Neurotrophic Factors for Diseases of the Nervous System

Targeting brain-derived neurotrophic factor in the treatment of neurodegenerative diseases: A review

Recent progress in studies of neurotrophic factors and their clinical implications

Targeting Emerging Pathogenic Mechanisms by Natural Molecules as Potential Therapeutics for Neurodegenerative Diseases

Development of Microrna-Based Therapeutics for Central Nervous System Diseases.

Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications

Delivery of Neuroregenerative Proteins to the Brain for Treatments of Neurodegenerative Brain Diseases

Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy

Modulatory Effects of Natural Products on Neuronal Differentiation

Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach

Gene Therapy for Neurodegenerative Disorders: Advances, Insights and Prospects

Efficient Delivery of Nerve Growth Factors to the Central Nervous System for Neural Regeneration.

Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases

Therapeutic Potential of Natural Compounds from Herbs and Nutraceuticals in Alleviating Neurological Disorders: Targeting the Wnt Signaling Pathway

The Use of Neurotrophic Factors as a Promising Strategy for the Treatment of Neurodegenerative Diseases (Review)

Structural Diversity of Neuritogenic Substances and Their Application Perspective

Recent Advances in Nanotherapeutics for Neurological Disorders

BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases

New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders